Furthermore, clinical studies have shown that GSDMD, T-tau, and Tau181p levels are increased in the cerebrospinal fluid of AD patients relative to normal population and VD (vascular dementia) patients, while the levels of Aβ1-42 are decreased (Shen et al., 2021). The gene discussed is MAPT; the disease is Alzheimer disease.